We are live on ! Find out more
TECH icon

Bio-Techne

528 hedge funds and large institutions have $12.3B invested in Bio-Techne in 2023 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 206 increasing their positions, 189 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

151% more call options, than puts

Call options by funds: $20.8M | Put options by funds: $8.3M

80% more funds holding in top 10

Funds holding in top 10: 59 (+4)

12% more capital invested

Capital invested by funds: $11.1B → $12.3B (+$1.28B)

1.25% more ownership

Funds ownership: 94.76%96.01% (+1.3%)

9% more repeat investments, than reductions

Existing positions increased: 206 | Existing positions reduced: 189

4% less funds holding

Funds holding: 549528 (-21)

25% less first-time investments, than exits

New positions opened: 52 | Existing positions closed: 69

Holders
528
Holders Change
-21
Holders Change %
-3.83%
% of All Funds
8.29%
Holding in Top 10
9
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+80%
% of All Funds
0.14%
New
52
Increased
206
Reduced
189
Closed
69
Calls
$20.8M
Puts
$8.3M
Net Calls
+$12.5M
Net Calls Change
+$3.23M
Name Holding Trade Value Shares
Change
Change in
Stake
First Trust Advisors
51
First Trust Advisors
Illinois
$48.2M -$10.2M -126,279 -18%
Dimensional Fund Advisors
52
Dimensional Fund Advisors
Texas
$46.7M +$206K +2,563 +0.4%
Swiss National Bank
53
Swiss National Bank
Switzerland
$46.4M -$4.43M -55,100 -9%
Bank of America
54
Bank of America
North Carolina
$45.8M -$5.65M -70,293 -11%
Deutsche Bank
55
Deutsche Bank
Germany
$44.9M -$13.3M -165,223 -23%
RA
56
Royce & Associates
New York
$44.5M -$12M -149,564 -22%
SCP
57
Sandhill Capital Partners
New York
$41M +$112K +1,388 +0.3%
N
58
Nuveen
North Carolina
$39.8M -$714K -8,883 -2%
Balyasny Asset Management
59
Balyasny Asset Management
Illinois
$34.4M -$9.11M -113,384 -21%
UBS AM
60
UBS AM
Illinois
$34.1M
Royal Bank of Canada
61
Royal Bank of Canada
Ontario, Canada
$33M +$1.12M +13,959 +4%
MAM
62
Montanaro Asset Management
United Kingdom
$31.7M +$80.4K +1,000 +0.3%
Handelsbanken Fonder
63
Handelsbanken Fonder
Sweden
$31.3M -$1.66M -20,700 -5%
RhumbLine Advisers
64
RhumbLine Advisers
Massachusetts
$28.4M +$285K +3,543 +1%
EP
65
Eversept Partners
New York
$28M +$12.4M +153,978 +82%
PM
66
Pembroke Management
Quebec, Canada
$27.7M +$2.78M +34,586 +11%
VOYA Investment Management
67
VOYA Investment Management
Georgia
$26.6M -$30.1M -374,784 -53%
State Farm Mutual Automobile Insurance
68
State Farm Mutual Automobile Insurance
Illinois
$26.2M
PAMS
69
Pictet Asset Management (Switzerland)
Switzerland
$25.6M +$589K +7,326 +2%
BAM
70
Broadcrest Asset Management
Florida
$24.5M +$4.02M +50,000 +20%
Barclays
71
Barclays
United Kingdom
$24.4M +$13M +161,922 +118%
NIG
72
NFJ Investment Group
Texas
$23.8M -$3.15M -39,147 -12%
SCA
73
Summit Creek Advisors
Minnesota
$23.2M +$22.6K +281 +0.1%
California Public Employees Retirement System
74
California Public Employees Retirement System
California
$22.6M -$1.18M -14,684 -5%
Amundi
75
Amundi
France
$22.4M -$15.8M -196,862 -42%

TECH Hedge Fund Activity: Q2 2023 in Review

528 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Bio-Techne (TECH) for Q2 2023, worth a combined $12.3B — up 12% from $11.1B a quarter earlier.

Sellers outnumbered buyers: 69 funds closed out of TECH and 52 opened new positions — a net loss of 17 holders — while 189 trimmed existing stakes and 206 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $286M. The largest seller was Select Equity Group, cutting an estimated $90.6M.

  • 528 institutional investors held Bio-Techne (TECH) as of Q2 2023, down from 549 in Q1 2023.
  • Funds reported $12.3B of Bio-Techne stock for Q2 2023, up 12% quarter-over-quarter.
  • 52 funds opened new Bio-Techne positions in Q2 2023 and 69 closed out, a net change of -17 holders.
  • The largest Bio-Techne buyer in Q2 2023 was T. Rowe Price Associates, an estimated $286M added.
  • The largest Bio-Techne seller in Q2 2023 was Select Equity Group, an estimated $90.6M sold.

Based on aggregated 13F filings for Q2 2023.